01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
00:19 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Coherus

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said SVP and CMO John Lawrence has resigned to pursue a new position with an undisclosed pharma company. Coherus BioSciences Inc. (NASDAQ:CHRS) hired Darlene Horton as chief medical and...
21:26 , Dec 4, 2018 |  BC Extra  |  Politics & Policy

Biosimilar makers back Pfizer in call to end misleading brand marketing

A group of biosimilar manufacturers including Pfizer Inc. (NYSE:PFE) urged FDA to produce supplemental guidance clarifying how to comply with existing law when communicating about biosimilars. The Biosimilars Forum sent its plea in a letter...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
17:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves AcelRx, Coherus, Pfizer Products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Nov. 2, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up...
21:15 , Nov 2, 2018 |  BC Extra  |  Company News

FDA approves AcelRx, Coherus, Pfizer products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Friday, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up $0.70...
19:55 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

FDA approves Coherus' Neulasta biosimilar

Coherus Biosciences Inc. (NASDAQ:CHRS) said FDA approved Udenyca pegfilgrastim-cbqv to treat cancer patients receiving myelosuppressive chemotherapy. Udenyca is the second FDA-approved biosimilar of neutropenia drug Neulasta drug pegfilgrastim. The European Commission also approved Udenyca for...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...